Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy

YJ Shimada, JJ Passeri, AL Baggish, C O'Callaghan… - JACC: Heart Failure, 2013 - jacc.org
Objectives: The aim of this study was to evaluate the effects of losartan on left ventricular
(LV) hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy …

Anabolic androgenic steroid induced myocardial toxicity: an evolving problem in an ageing population

RD Rothman, RB Weiner, H Pope, G Kanayama… - Case …, 2011 - casereports.bmj.com
Widespread use of anabolic androgenic steroid (AAS) abuse is a rapidly increasing public
health concern with an expanding demographic. Previous studies and reports have been …

Management strategy in 249 consecutive patients with obstructive hypertrophic cardiomyopathy referred to a dedicated program

RD Rothman, AL Baggish, C O'Callaghan… - The American journal of …, 2012 - Elsevier
The likelihood of success of conservative management of obstructive hypertrophic
cardiomyopathy (HC) and the predictors of failure of conservative therapy are not known. We …

Symptomatic gastric sarcoidosis in a patient with pulmonary sarcoidosis in remission

LE Shkolnik, RD Shin, DM Brabeck… - Case Reports, 2012 - casereports.bmj.com
Sarcoidosis is a multisystem, non-infectious, granulomatous disease of unknown cause,
characterised by histological evidence of non-caseating granulomas. Gastrointestinal (GI) …

[HTML][HTML] Risk stratification for sudden cardiac death after septal myectomy

RD Rothman, MA Safiia, PA Lowry, T Mela… - Journal of Cardiology …, 2011 - Elsevier
Background The importance of risk stratification for sudden cardiac death (SCD) after septal
myectomy for hypertrophic obstructive cardiomyopathy (HOCM) has not been emphasized …

The relationship between the follow-up to discharge ratio and length of stay.

RD Rothman, CM Whinney, MA Pappas… - The American Journal …, 2020 - europepmc.org
Objectives Average length of stay (ALOS) is used as a measure of the effectiveness of care
delivery and therefore is an important operational measure when evaluating both the …

Attenuation of Left Ventricular Fibrosis by Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A Randomized, Placebo Controlled, Double Blind …

YJ Shimada, JJ Passeri, AL Baggish, C O'Callaghan… - 2013 - Am Heart Assoc
Introduction: Despite evidence that left ventricular (LV) hypertrophy and fibrosis are
mediated by angiotensin II and are important determinants of morbidity and mortality in …

[CITATION][C] Early experience and lessons following the implementation of a Hospital‐at‐Home program

RD Rothman, CP Delaney, BM Heaton… - Journal of Hospital …, 2024 - Wiley Online Library
Healthcare is at a crossroads. Hospital admissions are increasing as staffing challenges
remain—exacerbated by workforce departures, increased labor costs, and facility closures. 1 …

[CITATION][C] Improving Healthcare Value: Managing Length of Stay and Improving the Hospital Medicine Value Proposition.

RD Rothman, DJ Peter, BJ Harte - Journal of hospital medicine, 2021 - europepmc.org
Improving Healthcare Value: Managing Length of Stay and Improving the Hospital Medicine
Value Proposition. - Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe …

Right Heart Failure Predicts Higher Mortality in Patients With Hypertrophic Cardiomyopathy

SA McCullough, YJ Shimada, AL Baggish, PA Lowry… - Circulation, 2014 - Am Heart Assoc
Introduction: The clinical correlates of right heart failure (RHF) and its association with
mortality in hypertrophic cardiomyopathy (HCM) have not been reported previously …